Incidences of Herpes Zoster and Acne by Age in Japanese Patients With Atopic Dermatitis During Treatment With Baricitinib or Upadacitinib: A Single-Centre Retrospective Study.
作者信息
Watanabe Ayu, Kamata Masahiro, Okada Yoshiki, Tomura Yayoi, Tada Yayoi
机构信息
Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
出版信息
Exp Dermatol. 2025 Apr;34(4):e70100. doi: 10.1111/exd.70100.
Abstract
摘要
相似文献
1
Incidences of Herpes Zoster and Acne by Age in Japanese Patients With Atopic Dermatitis During Treatment With Baricitinib or Upadacitinib: A Single-Centre Retrospective Study.
Exp Dermatol. 2025 Apr;34(4):e70100. doi: 10.1111/exd.70100.
2
Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib.
J Dermatol. 2023 Oct;50(10):1301-1312. doi: 10.1111/1346-8138.16879. Epub 2023 Jul 3.
3
A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis.
JAAD Int. 2021 Dec 20;6:27-36. doi: 10.1016/j.jdin.2021.11.001. eCollection 2022 Mar.
4
Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.
Inflamm Res. 2023 Sep;72(9):1861-1871. doi: 10.1007/s00011-023-01789-x. Epub 2023 Sep 14.
5
Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan.
J Dermatolog Treat. 2023 Dec;34(1):2276043. doi: 10.1080/09546634.2023.2276043. Epub 2023 Dec 10.
6
Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study.
Dermatol Ther (Heidelb). 2023 Aug;13(8):1817-1830. doi: 10.1007/s13555-023-00961-9. Epub 2023 Jun 25.
7
A real-world Australian experience of upadacitinib for the treatment of severe atopic dermatitis.
Australas J Dermatol. 2023 Nov;64(4):e352-e356. doi: 10.1111/ajd.14139. Epub 2023 Jul 31.
8
Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.
Front Immunol. 2024 Feb 23;15:1342810. doi: 10.3389/fimmu.2024.1342810. eCollection 2024.
9
Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
Dermatol Ther. 2022 Sep;35(9):e15636. doi: 10.1111/dth.15636. Epub 2022 Jul 27.
10
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21.
引用本文的文献
1
Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis Patients over and under 65 Years of Age: A Real-World Comparative Analysis.
Inflamm Intest Dis. 2025 Jun 24;10(1):180-186. doi: 10.1159/000546640. eCollection 2025 Jan-Dec.
本文引用的文献
1
Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study.
Dermatol Ther (Heidelb). 2023 Aug;13(8):1817-1830. doi: 10.1007/s13555-023-00961-9. Epub 2023 Jun 25.
2
Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence.
JID Innov. 2023 Feb 24;3(3):100195. doi: 10.1016/j.xjidi.2023.100195. eCollection 2023 May.
3
The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27.
Zotero 插件